title: A novel function of IL-12p40 as a chemotactic molecule for macrophages.
abstract: IL-12p70 plays a pivotal role in regulating the Th1/Th2 balance in the initial stage of immune responses. In contrast, IL-12p40, which is produced excess over IL-12p70, has been known to down-regulate IL-12p70-mediated responses by acting as an antagonist. To investigate in vivo function of IL-12p40, RH7777 rat hepatoma cells were engineered to inducibly express mouse IL-12p40 under the tight control of doxycycline (dox). In the absence of dox, s.c. injection of these cells into syngeneic rat was shown to generate tumors. However, the induction of IL-12p40 by dox was sufficient for inhibiting tumor formation, as well as for tumor regression. Immunohistochemical analysis showed that macrophages, but not CD4+ T, CD8+ T, and NK cells, were predominantly recruited into tumor sites as early as 3 days after IL-12p40 induction. These results were further supported by the observation that IL-12p40, but not C-terminal deletion mutants by more than 5 amino acids, was able to chemoattract peritoneal macrophages in vitro, suggesting that IL-12p40, when produced in a large excess over IL-12p70 in vivo, can initially amplify the immune responses against tumors by directly recruiting macrophages. Our findings indicate that IL-12p40 may function as an effector molecule as well as an antagonist of IL-12p70.
authors.affiliation: Department of Life Science, Center for Biofunctional Molecules, Pohang University of Science and Technology, Kyungbuk, Korea.
authors.forename: S J
authors.initials: SJ
authors.lastname: Ha
authors.forename: C H
authors.initials: CH
authors.lastname: Lee
authors.forename: S B
authors.initials: SB
authors.lastname: Lee
authors.forename: C M
authors.initials: CM
authors.lastname: Kim
authors.forename: K L
authors.initials: KL
authors.lastname: Jang
authors.forename: H S
authors.initials: HS
authors.lastname: Shin
authors.forename: Y C
authors.initials: YC
authors.lastname: Sung
mesh_terms: D000818:Animals; D019556:COS Cells; D006528:Carcinoma, Hepatocellular; D002465:Cell Movement / Q000276:immunology; D002630:Chemotactic Factors / Q000008:administration & dosage / Q000096:biosynthesis / Q000235:genetics / Q000502:physiology*; D004318:Doxycycline / Q000494:pharmacology; D005260:Female; D005822:Genetic Vectors / Q000008:administration & dosage; D018664:Interleukin-12 / Q000008:administration & dosage / Q000096:biosynthesis / Q000235:genetics / Q000378:metabolism / Q000502:physiology*; D008113:Liver Neoplasms / Q000209:etiology / Q000473:pathology / Q000628:therapy; D017737:Macrophages, Peritoneal / Q000276:immunology* / Q000473:pathology; D051379:Mice; D008807:Mice, Inbred BALB C; D009368:Neoplasm Transplantation; D010446:Peptide Fragments / Q000276:immunology / Q000378:metabolism / Q000502:physiology; D011485:Protein Binding / Q000276:immunology; D051381:Rats; D011915:Rats, Inbred BUF; D018123:Receptors, Interleukin / Q000378:metabolism; D053707:Receptors, Interleukin-12; D012075:Remission, Spontaneous; D014162:Transfection; D014407:Tumor Cells, Cultured
chemical_list: D002630:Chemotactic Factors; C508444:Il12rb2 protein, rat; D010446:Peptide Fragments; D018123:Receptors, Interleukin; D053707:Receptors, Interleukin-12; D018664:Interleukin-12; D004318:Doxycycline